RECRUITING Phase 1 / Phase 2 ClinicalTrials.gov

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

Sponsor: Curis, Inc. • ClinicalTrials.gov ID: NCT03328078

Registry updated: 2026-10-06

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

This is a multi-center, open-label study to evaluate the safety, pharmacokinetics (PK), and anti-cancer activity of oral administration of emavusertib alone or in combination with ibrutinib in adult participants with relapsed or refractory (R/R) hematologic malignancies. This trial will be completed in four parts. In Part A1, emavusertib will be evaluated first in a dose escalating monotherapy setting to establish the safety and tolerability (complete). In Part A2, emavusertib will be evaluated in combination with ibrutinib at 560 milligrams (mg) once daily (QD) or 420 mg QD as indicated by disease (Part A2 complete). Part B will comprise 2 cohorts to assess safety and efficacy of emavusertib in combination with ibrutinib in participants with R/R primary central nervous system lymphoma (PCNSL) who have directly progressed on a bruton tyrosine kinase inhibitor (BTKi). In this part of the study, emavusertib will be dosed at 100 mg or 200 mg twice daily (BID) in combination with ibrutinib in 28-day treatment cycles. Part C will comprise 3 treatment arms in the second-line setting to assess the efficacy and safety of emavusertib monotherapy, ibrutinib monotherapy, and emavusertib in combination with ibrutinib in participants with R/R PCNSL who are naïve to BTKi treatment. In this part of the study, eligible second-line participants with R/R PCNSL who are naïve to BTKi treatment will be randomized 1:1:1 to 1 of 3 treatment arms: (1) emavusertib 200 mg BID, (2) ibrutinib 560 mg QD, or (3) emavusertib 200 mg BID in combination with ibrutinib 560 mg QD.

Interventions

Emavusertib (Drug)
Emavusertib will be provided as a tablet dosage form to be taken BID.
Ibrutinib (Drug)
Ibrutinib will be provided as a tablet or capsule dosage form to be taken QD.

Eligibility criteria

Inclusion Criteria: 1. Males and females greater than or equal to 18 years of age 2. Life expectancy of at least 3 months 3. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or 2 4. Histopathologically confirmed diagnosis of PCNSL (medical record is acceptable). Cerebral biopsies are not required if imaging reveals typical images of PCNSL. 1. Participants with parenchymal lesions must have unequivocal evidence of disease progression (e.g., presence of at least 1 measurable target lesion \[≥ 10 millimeters (mm) and ≤ 40 mm in the longest diameter on brain magnetic resonance imaging \[MRI\] or head computed tomography \[CT\] on imaging within 28 days prior to Cycle 1 Day 1\]). In cases where the tumor size is smaller but still measurable and located at a critical central nervous system (CNS) location, disabling the participant and/or causing symptoms, this participant may be eligible following a discussion with the Sponsor Medical Monitor. 2. For participants limited to leptomeningeal involvement, cerebrospinal fluid (CSF) analysis (cytology and/or flow cytometry) with or without additional imaging (MRI) of the spine as clinically indicated is required to document abnormal cells within 28 days prior to Cycle 1 Day 1. Exclusion Criteria for Part B and Part C 1. Participants with only intraocular PCNSL without brain lesion or CSF involvement, T-cell lymphoma, systemic presence of lymphoma, or non-CNS lymphoma metastatic to the CNS 2. Evidence of systemic lymphoma. This must be demonstrated by a positron emission tomography (PET) scan (or CT scan with contrast if applicable) of the chest, abdomen, and pelvis at Screening (testicular ultrasound may be considered to exclude a testicular lymphoma disseminated to the brain). 3. Prior history of malignancies other than lymphoma (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast) or prior history of systemic lymphoma, unless the participant has been free of the disease for ≥ 3 years. 4. Active malignancy other than PCNSL requiring systemic therapy 5. Previous BTKi treatment (Part C only). 6. History of Grade ≥ 3 rhabdomyolysis without complete recovery 7. Requirement for urgent therapy due to uncontrolled tumor mass/edema effects. 8. Received external beam radiation therapy to the CNS within 28 days prior to Cycle 1 Day 1. 9. Received prior investigational drugs (including treatment in clinical research, unapproved combination products, and new dosage forms) within 28 days or 5 half-lives, whichever is shorter, prior to Cycle 1 Day 1; allogeneic hematopoietic stem cell transplant (HSCT) within 60 days prior to Cycle 1 Day 1; or had clinically significant graft-versus-host disease (GVHD) requiring ongoing up-titration of immunosuppressive medications prior to Screening (with the exception of a BTKi for Part B only). Note: The use of a stable or tapering dose of immunosuppressive therapy post-HSCT and/or topical steroids for ongoing skin GVHD is permitted with Sponsor Medical Monitor approval 10. Any prior systemic anti-cancer treatment such as chemotherapy, immunomodulatory drug therapy, etc., received within 14 days or 5 half-lives, whichever is shorter, prior to Cycle 1 Day 1 (with the exception of ibrutinib or other BTKi for Part B only, which may be continued until the day before Cycle 1 Day 1) 11. Prior history of hypersensitivity or anaphylaxis to emavusertib, ibrutinib or any of their excipients.

Conditions

Relapsed Hematologic Malignancy Refractory Hematologic Malignancy Relapsed Primary Central Nervous System Lymphoma Refractory Primary Central Nervous System Lymphoma

Locations

St. Joseph's Hospital and Medical Center — Phoenix, Arizona, United States
Mayo Clinic — Phoenix, Arizona, United States
City of Hope — Duarte, California, United States
Providence St. John's Health Center — Santa Monica, California, United States
UCLA Department of Medicine - Hematology/Oncology — Santa Monica, California, United States
Smilow Cancer Hospital at Yale-New Haven — New Haven, Connecticut, United States
Mayo Clinic — Jacksonville, Florida, United States
Northwestern Memorial Hospital — Chicago, Illinois, United States
Dana Farber Cancer Institute — Boston, Massachusetts, United States
Mayo Clinic — Rochester, Minnesota, United States
Fred and Pamela Buffett Cancer Center — Omaha, Nebraska, United States
Hackensack University Medical Center — Hackensack, New Jersey, United States
Roswell Park Comprehensive Cancer Center — Buffalo, New York, United States
Mt Sinai — New York, New York, United States
Columbia University Irving Medical Center — New York, New York, United States
Memorial Sloan Kettering Cancer Center — New York, New York, United States
Duke University Medical Center, Duke Cancer Center — Durham, North Carolina, United States
Cleveland Clinic — Cleveland, Ohio, United States
Providence Neurological Specialties West — Portland, Oregon, United States
Hospital of the University of Pennsylvania — Philadelphia, Pennsylvania, United States
UPMC Hilman Cancer Center — Pittsburgh, Pennsylvania, United States
University of Tennessee Medical Center — Knoxville, Tennessee, United States
UT Southwestern Medical Center — Dallas, Texas, United States
The University of Texas MD Anderson Cancer Center — Houston, Texas, United States
Huntsman Cancer Institute, University of Utah — Salt Lake City, Utah, United States
Swedish Cancer Institute — Seattle, Washington, United States
University of Washington Medical Center — Seattle, Washington, United States
Všeobecná fakultní nemocnice v Praze — Prague, Czechia
Institut Bergonie — Bordeaux, France
Hopital de la Timone — Marseille, France
Hospital Pitie Salpetriere — Paris, France
Institut Curie Hospital — Paris, France
Hematology Department Soroka UMC / Heanatology Department — Beersheba, Israel
Rambam Medical Center — Haifa, Israel
Hadassah Medical Center / Ein-Carem — Jerusalem, Israel
Università di Torino Croce e Carle — Cuneo, Italy
SODc Ematologia Azienda Ospedaliera Universitaria Careggi — Florence, Italy
IRST - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori — Meldola, Italy
IRCCS San Raffaele Scientific Institute — Milan, Italy
Uniwersyteckie Centrum Kliniczne Osrodek Badan Klinicznych Wczesnych Faz — Gdansk, Poland
Oddzial Kliniczny Hematologii — Krakow, Poland
NarodowyInstytutu Onkologii im. Marii Sklodowskiej-Curie-Panstwowy Instytutu Badawczy — Warsaw, Poland
University Hospital Vall d'Hebron — Barcelona, Spain
MD Anderson Cancer Center Madrid — Madrid, Spain
Hospital Universitario Virgen del Rocio — Seville, Spain

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment